Condition: Advanced Cancer · Sponsor: NYU Langone Health
The purpose of this research is to study the safety and effects of single-dose psilocybin 25mg versus an active placebo (single dose niacin 100mg) in the treatment of anxiety, depression, and existential distress (i.e., loss of meaning and hope; fear of death) in advanced cancer (i.e., stage 3 or 4). Study medications will be administered in conjunction with brief psychotherapy that is designed to treat anxiety, depression and existential distress in advanced cancer.
This description comes directly from the study's public registry record.
Sydney Weiner, MA · 212-263-6283 · sydney.weiner@nyulangone.org
Stephen Ross, MD · 212-263-6289 · stephen.ross@nyulangone.org
Always discuss trial participation with your own doctor first.
| University of Colorado Anschutz Medical campus (CU AMC) | Aurora, Colorado, United States | Recruiting |
| NYU Langone Health | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05398484